CD34 and hereditary disease: For obvious reasons, this should be avoided since CD34+ cells are rare and isolation of sufficient CD34+ cells for gene therapy can be a challenging task, especially in the case of BM failures, a family of genetic diseases that affects directly the HSPCs decreasing their numbers with age in the patients (Verhoeyen et al., 2017).